SCHEMBL3631901

SCHEMBL3631901

O[C@H]1C[C@@H](N2CCCC2)C1

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.42
CYP2C9 P11712 1/20 0.42
FYN P06241 1/20 0.37
L3MBTL3 Q96JM7 6/20 0.34
L3MBTL1 Q9Y468 5/20 0.34
HTR6 P50406 1/20 0.34
MBTD1 Q05BQ5 4/20 0.33
LTA4H P09960 1/20 0.33
TP53BP1 Q12888 1/20 0.33
L3MBTL4 Q8NA19 1/20 0.33
HRH3 Q9Y5N1 1/20 0.33
PKM P14618 1/20 0.32
POLB P06746 1/20 0.32
MEN1 O00255 1/20 0.32
CYP2D6 P10635 1/20 0.32
KMT2A Q03164 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3631897 1.00 LMNA (0.42) LMNACYP2C9FYNL3MBTL3L3MBTL1
SCHEMBL3750473 0.97 LMNA (0.40) LMNACYP2C9FYNL3MBTL3L3MBTL1
SCHEMBL3750471 0.97 LMNA (0.40) LMNACYP2C9FYNL3MBTL3L3MBTL1
SCHEMBL1431972 0.97 LMNA (0.40) LMNACYP2C9FYNL3MBTL3L3MBTL1
SCHEMBL1431971 0.97 LMNA (0.40) LMNACYP2C9FYNL3MBTL3L3MBTL1
SCHEMBL3671458 0.81 PHGDH (0.45) LMNACYP2C9L3MBTL3L3MBTL1HRH3
SCHEMBL3671457 0.81 PHGDH (0.45) LMNACYP2C9L3MBTL3L3MBTL1HRH3
SCHEMBL2115057 0.80 CYP2C9 (0.46) LMNACYP2C9MEN1KMT2A
SCHEMBL3138231 0.79 LMNA (0.46) LMNACYP2C9FYNL3MBTL3L3MBTL1
SCHEMBL3127379 0.79 LMNA (0.46) LMNACYP2C9FYNL3MBTL3L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100305116-A1 Compounds Comprising a Cyclobutoxy Group UCB PHARMA, S.A. (BE) 2010-12-02 US claimed
EP-2146980-A2 HISTAMINE H3 RECEPTOR LIGANDS COMPRISING A CYCLOBUTOXY GROUP UCB Pharma S.A. (BE) 2010-01-27 EP claimed
WO-2008128919-A2 HISTAMINE H3 RECEPTOR LIGANDS COMPRISING A CYCLOBUTOXY GROUP UCB PHARMA S.A. (BE) 2008-10-30 WO claimed
US-12630562-B2 Piperidylurea compounds and methods of use thereof ARCUS BIOSCIENCES, INC. (US) 2026-05-19 US disclosed
US-20260042777-A1 PIPERIDYLUREA COMPOUNDS AND METHODS OF USE THEREOF ARCUS BIOSCIENCES, INC. (US) 2026-02-12 US disclosed
US-20100305116-A1 Compounds Comprising a Cyclobutoxy Group UCB PHARMA, S.A. (BE) 2010-12-02 US disclosed
US-20100292188-A1 Compounds Comprising A Cyclobutoxy Group UCB PHARMA S.A. (BE) 2010-11-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305116-A1 Compounds Comprising a Cyclobutoxy Group HMGCR, TECR, CYP4A11 LMNA 1421/4885CYP2C9 102/4885FYN 113/4885
US-12630562-B2 Piperidylurea compounds and methods of use thereof CLIC1, HCCS, CNR1 LMNA 826/4885CYP2C9 249/4885FYN 3201/4885
US-20100292188-A1 Compounds Comprising A Cyclobutoxy Group CYP11B2, CYP11B1, CYP4B1 LMNA 2612/4885CYP2C9 10/4885FYN 745/4885
US-20260042777-A1 PIPERIDYLUREA COMPOUNDS AND METHODS OF USE THEREOF CBR1, CLIC1, RER1 LMNA 1052/4885CYP2C9 527/4885FYN 3219/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.